Vemurafenib/dabrafenib and trametinib-Reference-Cited by-同舟云学术

Vemurafenib/dabrafenib and trametinib

Published:2015-06-11 Issue:4 Volume:80 Page:765-767
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Rissmann Robert¹²,Hessel Marleen H. M.²,Cohen Adam F.¹²^ORCID

Affiliation:

1. Centre for Human Drug Research; Leiden the Netherlands

2. Leiden University Medical Center; Leiden the Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12651/fullpdf

Reference8 articles.

1. Vemurafenib;Flaherty;Nat Rev Drug Discov,2011

2. European Medicines Agency Zelboraf: EPAR - Product Information http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002409/WC500124317.pdf

3. European Medicines Agency Tafinlar: EPAR - Product Information http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002604/WC500149671.pdf

4. European Medicines Agency Mekinist: EPAR - Product Information http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002643/WC500169657.pdf

5. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations;Flaherty;N Engl J Med,2012

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System Events for Trametinib;Cureus;2024-08-27

2. Case 2-2024: A 57-Year-Old Woman with Melanoma and Fever;New England Journal of Medicine;2024-01-18

3. The mystery of titan hunter: Rationalized striking of the MAPK pathway via Newly synthesized 6‐Indolylpyridone‐3‐Carbonitrile derivatives;European Journal of Medicinal Chemistry;2023-11

4. Potential drug–drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma;Expert Opinion on Drug Metabolism & Toxicology;2023-08-03

5. MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia;Leukemia;2023-06-29